Push into image networking continuesThe recent acquisition of E for M by Marquette Electronics ofMilwaukee demonstrates how medical device companies are, in increasingnumbers, joining forces to pair one firm's domestic product lineand
The recent acquisition of E for M by Marquette Electronics ofMilwaukee demonstrates how medical device companies are, in increasingnumbers, joining forces to pair one firm's domestic product lineand distribution strengths with another firm's brand name anddistribution advantages in overseas markets.
Strategic alliances between Acuson and Shimadzu, ATL and Hitachi,and merger/acquisitions involving Dornier and Acoustic Imaging,Schering and Medrad, and Sopha and Summit, were all designed towardthis end.
In this instance, Marquette CEO Michael Cudahy saw synergiesbetween Marquette's cardiology, patient monitoring and gas analysisproduct lines and the electrocardiography (ECG) and stress testsystems made by Hellige GmbH. Hellige is a Germany-based subsidiaryof E for M, which is headquartered in Torrance, CA.
The acquisition brings Hellige, a respected company with morethan 100 years of experience in the ECG field, into Marquette'scamp while greatly expanding Marquette's presence in Europe, accordingto Cudahy. The combined companies have worldwide sales exceeding$500 million and employ about 3000 people.
E for M will contribute about $200 million in annual sales,according to Michael Breedlove, vice president of field operations.European sales account for about two-thirds of that total.
The $89 million acquisition was completed in January when remainingE for M common stock was purchased at the initial offering priceof $12 per share, Breedlove said. The deal was announced lastNovember after board approval by the two publicly traded companies.
E for M CEO Peter Tong has been appointed co-president of Marquette.He will be responsible for the company's international business,as well as for a supplies division that sells ECG paper, disposableelectrodes and the Vari-X line of cine film designed for cardiaccatheterization labs, Breedlove said.
The E for M corporate identity will survive for business directedat cardiac cath labs, according to Breedlove. Businessformerlyhandled by Marquette's diagnostics group was carved off and combinedwith E for M cardiac cath and physiological monitoring marketingoperations. E for M's Torrance group also continues to managea separate 35-person sales force devoted to disposable productsales, he said.
"We now have a broad product line from one company toprovide all the needs of cardiac cath labs," he said.
Breedlove predicts few changes in E for M's effort to expandits reach into medical imaging. Its imaging systems division suppliesOEM customers with digital photospot products, display monitors,DICOM bridges, scan converters and other components. E for M,which for years sold its products through OEMs, flew its corporatecolors for the first time at the 1995 Radiological Society ofNorth America meeting.
Breedlove expects that the acquisition will lead to accelerateddevelopment of new products designed for image acquisition, reviewand long-term archiving.
"We have a major commitment to diagnostic imaging andto the continued growth of our product line," he said.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.